University of Colorado Hospital/ Anschutz Cancer Pavilion

Aurora, Colorado 88045

7 studies enrolling now · 36 studies all time

What they study most

Adenocarcinoma of the Prostate, Advanced Cancer, Advanced Epithelioid Sarcoma, Advanced Liver Cancers, Advanced Malignancies Except Leukemia, Advanced Melanoma, Advanced Or Metastatic Merkel Cell Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Solid Tumors, Alopecia Areata, B-cell Non-Hodgkin Lymphoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative

Studies at this site

• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — Recruiting now
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) — Recruiting now
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] — Recruiting now
• Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors — Recruiting now
• LYL273 for Patients With Relapsed or Refractory mCRC — Recruiting now
• Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma — Recruiting now
• A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases — Recruiting now
• Clinical Trial Multi-analyte Blood Test — Running, not enrolling
• A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) — Running, not enrolling
• Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — Running, not enrolling
• Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma — Stopped early
• ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer — Completed
• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling
• UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma — Completed
• A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma — Running, not enrolling
• Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer — Completed
• Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors — Stopped early
• A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) — Completed
• A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 — Completed
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) — Completed
• A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery — Stopped early
• A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer — Completed
• Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors — Completed
• Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma — Completed
• Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer — Completed
• A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies — Completed
• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata — Completed
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer — Completed
• A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy — Completed
• A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes — Completed
• PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib — Completed
• EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx — APPROVED_FOR_MARKETING